• Lōkahi Therapeutics, a GlucoTrack subsidiary, split its ai² platform into ai² Pipeline, ai² Talent, ai² Accelerator.
• Reorganization targets new revenue lines while maintaining its focus on late-stage therapeutic asset development.
• ai² expanded to 13 universities in about a year, screening more than 45 therapeutic assets; several moved into active diligence.
• New divisions position the platform for partnerships, licensing, fee-based services, workforce programs, asset origination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260908357637) on September 08, 2026, and is solely responsible for the information contained therein.